Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jaut.2020.102523 http://scihub22266oqcxt.onion/10.1016/j.jaut.2020.102523 32690352!7365106!32690352     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Autoimmun 2020 ; 114 (ä): 102523 Nephropedia Template TP {{tp|p=32690352|t=2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study |pdf=|usr=}}{{32690352}} gab.com Text Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study JO: J Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=32690352 #FOAvip OBJECTIVES: To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. PATIENTS AND METHODS: Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital (March 12 - May 2, 2020). Clinical outcomes: death, length of hospital stay. An early clinical response to TCZ (48-72 h after the administration) was assessed by variations in respiratory function markers, Brescia COVID Respiratory Severity Scale (BCRSS), inflammatory parameters, and patients' and physicians' opinion. Associations were tested by multiple logistic regression. RESULTS: From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 years (IQR 53.0-72.0), 64.9% were males), 42.9% had Charlson index >/=3; hypertension (41.6%), obesity (34.7%), and diabetes (20.8%). Median follow-up was 83.0 days (78.0-86.5), no patient was readmitted. ICU admission was required for 42 (54.5%), invasive mechanical ventilation in 38 (49.4%) and 10 patients died (12.9% global, 23.8% at ICU admitted). After multivariate adjustment, TCZ response by BCRSS (OR 0.03 (0.01-0.68), p = 0.028), and Charlson index (OR 3.54 (1.20-10.44), p = 0.022) has been identified as independent factors associated with mortality. Median of hospital stay was 16.0 days (11.0-23.0); BCRSS, physician subjective and D-dimer response were associated with shorter hospitalization stay. CONCLUSIONS: In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay. Twit Text FOAVip Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study ????J Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=32690352 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32690352 #FOAvip English Wikipedia <ref>{{Cite pmid|32690352}}</ref> Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study #MMPMID32690352 Moreno-Perez O; Andres M; Leon-Ramirez JM; Sanchez-Paya J; Rodriguez JC; Sanchez R; Garcia-Sevila R; Boix V; Gil J; Merino E J Autoimmun 2020[Nov]; 114 (ä): 102523 PMID32690352show ga OBJECTIVES: To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. PATIENTS AND METHODS: Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital (March 12 - May 2, 2020). Clinical outcomes: death, length of hospital stay. An early clinical response to TCZ (48-72 h after the administration) was assessed by variations in respiratory function markers, Brescia COVID Respiratory Severity Scale (BCRSS), inflammatory parameters, and patients' and physicians' opinion. Associations were tested by multiple logistic regression. RESULTS: From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 years (IQR 53.0-72.0), 64.9% were males), 42.9% had Charlson index >/=3; hypertension (41.6%), obesity (34.7%), and diabetes (20.8%). Median follow-up was 83.0 days (78.0-86.5), no patient was readmitted. ICU admission was required for 42 (54.5%), invasive mechanical ventilation in 38 (49.4%) and 10 patients died (12.9% global, 23.8% at ICU admitted). After multivariate adjustment, TCZ response by BCRSS (OR 0.03 (0.01-0.68), p = 0.028), and Charlson index (OR 3.54 (1.20-10.44), p = 0.022) has been identified as independent factors associated with mortality. Median of hospital stay was 16.0 days (11.0-23.0); BCRSS, physician subjective and D-dimer response were associated with shorter hospitalization stay. CONCLUSIONS: In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay. |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |Antiviral Agents/*administration & dosage[MESH] |Betacoronavirus/*immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/diagnosis/immunology/mortality/*therapy[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Follow-Up Studies[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Infusions, Intravenous[MESH] |Interleukin-6/immunology/metabolism[MESH] |Length of Stay/statistics & numerical data[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/immunology/mortality/*therapy[MESH] |Prognosis[MESH] |Receptors, Interleukin-6/antagonists & inhibitors/metabolism[MESH] |Respiration, Artificial/*statistics & numerical data[MESH] |Respiratory Function Tests/statistics & numerical data[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Spain/epidemiology[MESH] |Survival Analysis[MESH] |Time Factors[MESH] |Time-to-Treatment[MESH]Experience with tocilizumab in severe COVID-19 pneumonia after 80 days(epmc).pdf DeepDyve Pubget Overpricing